Skip to content

Effect of dexamethasone intravitreal implant on macular edema in vitrectomy eyes

Clinical observation of dexamethasone intravitreal implant in the treatment of diabetic macular edema in vitrectomy eyes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096153
Enrollment
Unknown
Registered
2025-01-20
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema after vitrectomy

Interventions

Case series:none

Sponsors

The second hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; No gender limit. 2. diagnosed as type 2 diabetes mellitus; Study eyes were diagnosed with PDR and underwent PPV, silicone oil removal, or silicone oil removal combined with cataract extraction and intraocular lens implantation >= 5 weeks after treatment. 3. The BCVA ? 20/25 (0.8) (Snellen visual acuity) of the study eyes was ? 20/25 (0.8). OCT scan CRT > 250 µm; 4. Informed consent was obtained from the patient to receive intravitreous injection of dexamethasone implant in the study eye; And willing to accept regular follow-up; 5. There was no history of glaucoma and related surgical history, and the intraocular pressure of the study eyes was <= 21 mmHg (1 mmHg = 0.133 KPa) without the use of intraocular pressure lowering drugs. 6. Nearly 2m patients had not received intravitreal injection of anti-VEGF drugs; He did not receive intravitreal injection of dexamethasone implants, triamcinolone acetonide (TA) and other glucocorticoid drugs within 6 months. He had not received subconjunctival or retrobulbar injection of glucocorticoids in the last 2m.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe heart disease, hypertension, abnormal liver and kidney function, abnormal coagulation function, etc., requiring specialized hospitalization; 2. Aphakic eyes, IOL eyes and anterior chamber IOL patients with incomplete posterior capsule and/or anterior capsule; 3. The study eyes had high myopia, refraction spherical equivalent -6>=.0DS; 4. Other serious eye diseases, such as corneal disease, cataract, glaucoma, uveitis, ocular hypertension, vitreous opacity and hemorrhage, optic nerve disease, age-related macular degeneration, retinal vein occlusion, pathological myopia fundus changes, rhegmatogenous retinal detachment and stage 3 or 4 macular hole, etc. 5. The study eyes were planned to undergo cataract surgery within six months; 6. Pregnant and lactating women; 7. High sensitivity constitution.

Design outcomes

Primary

MeasureTime frame
best corrected visual acuity;

Secondary

MeasureTime frame
intraocular pressure;foveal avascular zone, FAZ;Choroidal thickness;

Countries

China

Contacts

Public ContactFei Liu

The second hospital of Dalian Medical University

drliufei@163.com+86 411 8467 1291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026